New generation drug eluting stents in complex coronary interventions
نویسندگان
چکیده
منابع مشابه
Drug-eluting coronary-artery stents.
n engl j med 368;16 nejm.org april 18, 2013 1557 by Barbui et al., a consensus statement of which they are coauthors, contains no data addressing their assertion because, as Barbui has written elsewhere,1 there are no data implicating the baseline leukocyte count as a thrombotic risk factor in patients with polycythemia vera. Fourth, by choosing the reference by Campbell et al., they are confla...
متن کاملNew Drug-Eluting Stents
The introduction of drug-eluting stents (DES) has rapidly and profoundly affected the field of interventional cardiology, and DESs are now used in a majority of intracoronary stenting procedures. As a result of the innumerable “trial-and-error” endeavors, DESs have emerged as a potential solution for solving the problem of restenosis. DESs are coated stents capable of releasing single or multip...
متن کاملDrug-eluting coronary artery stents.
Many advances have been made in the percutaneous treatment of coronary artery disease during the past 30 years. Although balloon angioplasty alone is still performed, the use of coronary artery stents is much more common. Approximately 40 percent of patients treated with balloon angioplasty developed restenosis, and this was reduced to roughly 30 percent with the use of bare-metal stents. Howev...
متن کاملDrug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis).
This meta-analysis combined the results of randomized clinical trials to compare the efficacy of drug-eluting stents with that of bare metal stents in percutaneous coronary interventions to ascertain which revascularization strategy is most safe and effective. The literature identified 13 published studies, and 8 were included in the main meta-analysis, thus allowing a meta-analysis on 3,860 pa...
متن کاملThrombosis in Coronary Drug-Eluting Stents
Coronary drug-eluting stents (DES) were first approved for use in the United States in 2003 (Cypher Coronary Sirolimus-Eluting Stent [SES], Cordis Corporation, Miami Lakes, Fla) and 2004 (Taxus Express Paclitaxel-Eluting Stent [PES], Boston Scientific Corporation, Natick, Mass) on the basis of randomized, blinded, controlled studies that demonstrated reduced target vessel failure (Cypher) and t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cardiologia Croatica
سال: 2018
ISSN: 1848-543X,1848-5448
DOI: 10.15836/ccar2018.392